Non-invasive skin cholesterol testing: a potential proxy for LDL-C and apoB serum measurements

Abstract Background Lipid management is the first line of treatment for decreasing the incidence of cardiovascular events in patients with coronary heart disease (CHD), and a variety of indicators are used to evaluate lipid management. This work analyses the differences in LDL-C and apoB for lipid management evaluation, as well as explores the feasibility of skin cholesterol as a marker that can be measured non-invasively for lipid management. Methods The prospective study enrolled 121 patients who had been diagnosed with acute coronary syndrome (ACS) at the department of emergency medicine of the First Affiliated Hospital of the USTC from May 2020 to January 2021, and the patients were grouped into Group I (n=53) and Group II (n=68) according to whether they had comorbid hyperlipidemia and/or diabetes mellitus. All patients were administered 10 mg/day of rosuvastatin and observed for 12 weeks. Lipid management was assessed on the basis of LDL-C and apoB, and linear correlation models were employed to assess the relationship between changes in these well accepted markers to that of changes in skin cholesterol. Results Out of 121 patients with ACS, 53 patients (43.80 %) had combined hyperlipidemia and/or diabetes mellitus (Group I), while 68 patients (56.20 %) did not (Group II). Cardiovascular events occur at earlier ages in patients with CHD who are comorbid for hyperlipidemia and/or diabetes (P<0.05). LDL-C attainment rate is lower than apoB attainment rate with rosuvastatin therapy (P<0.05), which is mainly attributable to patients with low initial LDL-C. Skin cholesterol reduction correlated with LDL-C reduction. (r=0.501, P<0.001) and apoB reduction (r=0.538, P<0.001). Skin cholesterol reduction continued over all time points measured. Conclusions Examination of changes in apoB levels give patients with low initial LDL-C more informative data on lipid management than LDL-C readings. In addition, non-invasive skin cholesterol measurements may have the potential to be used independently for lipid management evaluation.

Download Full-text

Outcome of Patients Hospitalized with Acute Coronary Syndrome Fulfilling the Criteria of Metabolic Syndrome

Journal of Medicine ◽

10.3329/jom.v15i1.19857 ◽

2014 ◽

Vol 15 (1) ◽

pp. 31-35

Author(s):

Mohammed Shahadat Hossain ◽

Khan Abul Kalam Azad ◽

Prodip Kumar Biswas ◽

Md. Amir Hossain ◽

Jayanta Kumar Saha ◽

...

Keyword(s):

Diabetes Mellitus ◽

Metabolic Syndrome ◽

Acute Coronary Syndrome ◽

Heart Block ◽

Cardiovascular Complications ◽

Coronary Syndrome ◽

Group I ◽

Significant Difference ◽

Group Ii ◽

The Impact

The aim of the study was to assess the association of metabolic syndrome in patients with acute coronary syndrome and the impact of metabolic syndrome on clinical outcome. Total 210 ACS patients were included in this study and divided in group I & II on the basis of presence or absence of MS respectively. Among the study patients mean age in group I and group II was 52.99 ± 11.49 years and 53.34 ± 12.54 years respectively. Among the risk factors, hypertension (70%vs 15%), dyslipidemia (100 vs. 97%), diabetes mellitus (36.4% vs. 6%) were significant between two groups. Mean waist circumference recorded was 103.12 ± 4.15 in group I and 96.50 ± 6.43 in group II which was significant. Present study showed, in hospital outcome was worse in group I in comparison to group II and was significant, like cardiogenic shock (11% vs. 1%), LVF (28.2% vs. 16%), and CVD (5.45 vs. 0%). But there were no significant difference in heart block, tachyarrhythmia, cardiac arrest, reinfarction and death. Complications were far more in group I than in group II (14.5% vs. 52.0%) which was also highly significant. So, we conclude that the presence of MS in patients suffered from ACS was associated with a greater incidence of in-hospital cardiovascular complications and mortality.DOI: http://dx.doi.org/10.3329/jom.v15i1.19857 J Medicine 2014; 15: 31-35

Download Full-text

Frequency of Vitamin B12 Deficiency in Pregnant Women with Gestational Diabetes Mellitus

10.53350/pjmhs2115102753 ◽

2021 ◽

Vol 15 (10) ◽

pp. 2753-2755

Author(s):

Shazia Jamil ◽

Naveed Mahmood ◽

Israr-ul- Haque ◽

Rabiah Haque ◽

Muhammad Imran-ul-Hasan ◽

...

Keyword(s):

Diabetes Mellitus ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Vitamin B12 ◽

Pregnant Women ◽

Vitamin B12 Deficiency ◽

Group I ◽

B12 Deficiency ◽

Vitamin B 12 ◽

Group Ii

Objective: To determine the prevalence of vitamin B-12 deficiency in pregnant women with gestational diabetes mellitus. Study Design: Retrospective study Place and Duration of Study: Department of Medicine, OMC Hospital, Jail Road Lahore from January, 2020 to December, 2020. Methods: Two hundred and thirty pregnant females were enrolled age between 18-45 years. Detailed demographics of enrolled cases age, gestational age, gravidity and body mass index were recorded after taking informed written consent. Among 230 cases, 100 women were non GDM (group I) and 130 had gestational diabetes mellitus (group II). Blood samples were taken from all the patients for measuring vitamin B12 status. Vitamin B12 was defined as <300 pg/ml. Results: Mean age of the patients in group I was 31.64±7.45 years with mean BMI 25.88±8.65 kg/m2 while mean age among GDM group was 34.55±5.71 years with mean BMI 27.36±9.44 kg/m2. Mean gestational age in group I was 33.72±4.21 weeks and in group II 35.08±9.27 weeks. In group I 20 (20%) had vitamin B12 deficiency and in group II rate ofvitamin B12 deficiency was high among 90 (69.2%) cases. We found a significantly relation between vitamin B12 and GDM with p value <0.0007. Conclusion: The prevalence of vitamin B-12 deficiency among pregnant women of gestational diabetes mellitus was significantly high as compared to normal pregnant women. Keywords: Pregnant Women, Gestational Diabetes Mellitus, Vitamin B12 deficiency

Download Full-text

Study of the Osteoporotic Changes in Postmenopausal Women with Type-2 Diabetes Mellitus

Bangladesh Journal of Nuclear Medicine ◽

10.3329/bjnm.v18i1.34929 ◽

2017 ◽

Vol 18 (1) ◽

pp. 21-26

Author(s):

Ayesha Jahan ◽

Rokeya Begum ◽

Khaled Bin Shamsuddin

Keyword(s):

Diabetes Mellitus ◽

Bone Mineral Density ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Femoral Neck ◽

Postmenopausal Women ◽

Mineral Density ◽

Group I ◽

Group Ii

Introduction: Osteoporosis and Diabetes Mellitus (DM) are common medical conditions in the society with an increasing prevalence in elderly people. Osteoporosis is more common in female than male and postmenopausal women are vulnerable to it. Objective: The aim of this study was to verify the effect of type-2 diabetes mellitus on bone mineral density in postmenopausal women and, thereby, to evaluate the risk of osteoporosis in them. Materials and Methods: This cross-sectional study was carried out at National institute of Nuclear Medicine and Allied Sciences (NINMAS), BSMMU campus, Shahbagh, Dhaka, over a period of one year. 175 postmenopausal women were enrolled as study subjects, among them 72 (41.10%) were diabetic and rest 103 (59.90%) were nondiabetic and they were assigned as Group-I and Group-II respectively. The bone mineral density (BMD) was measured by central DEXA device at lumbar spines and left femoral neck of each study subject. Results: The mean (±SD) ages of group-I and group-II were 58.79 (±8.06) and 58.27 (±8.39) respectively with an age range of 45 to 75 years in both cases. A total of 30 (41.66%) patients in diabetic group (group-I) and 40 (38.83%) patients in non-diabetic (group-II) had osteoporosis at lumbar spines. On the other hand, 40 (56.94%) patients in group-I and 58 (56.31%) patients in group-II had osteoporosis at femoral neck. The Odds Ratios of osteoporosis for lumbar spines and femoral. neck were 1.125 and 1.026 respectively. The differences of frequencies of osteoporosis between group-I and group-II were not statistically significant at any anatomical site and the association between osteoporosis and type-2 diabetes mellitus was not significant. According to Odds Ratio type-2 diabetes mellitus was not a risk factor for developing osteoporosis in postmenopausal women. Conclusion: Postmenopausal women are prone to develop osteoporosis and type-2 diabetes mellitus may have adverse influence on osteoporosis, which was supported by few previous studies. This study could not establish any significant effect of type-2 diabetes mellitus on osteoporosis in postmenopausal women.Bangladesh J. Nuclear Med. 18(1): 21-26, January 2015

Download Full-text

Electroneurographic parameters in patients with metabolic syndrome

Journal of Health Sciences ◽

10.17532/jhsci.2014.144 ◽

2014 ◽

Vol 4 (1) ◽

pp. 45-49

Author(s):

Suljo Kunić ◽

Emir Tupković ◽

Mediha Nišić ◽

Semiha Salihović

Keyword(s):

Diabetes Mellitus ◽

Metabolic Syndrome ◽

Glycemic Control ◽

Action Potential ◽

Median Nerve ◽

Ulnar Nerve ◽

Sensory Nerve ◽

Group I ◽

Patients With Diabetes ◽

Group Ii

Introduction: The aim of this study was to measure electroneurographic (ENG) parameters of the median and ulnar nerve in patients with metabolic syndrome and to determine whether the large imbalance in glycemic control came to neuropathic changes to the template.Methods: The study included 100 patients with metabolic syndrome diagnosed according to the criteria of the National Cholesterol Education Program - Adult Treatment Panel III (NCEP-ATP III). The patients were divided into two groups. Group I – patients with normal glycemic control and Group II - patients with diabetes mellitus for up to five years. We measured sensory conductive velocity (SCV), the amplitude of sensory nerve action potential (SNAP), motor conductive velocity (MCV), terminal motor latency (TML) and compose muscle action potential after distal stimulation (CMAP-I) and after proximal stimulation (CMAP-II) for the ulnar and median nerve.Results: Sensory and motor parameters in Group II were amended to neuropathic pattern compared to Group I. There were significant differences in: SNAP amplitude for all tested nerves, SCV values for both left and right median and ulnar nerve; MCV and TML for left median nerve; MCV, TML and CMAP-I for right median nerve area; MCV and TML for left ulnar nerve; MCV, CMAP-I and CMAP-II for right ulnar nerve area.Conclusion: Patients with metabolic syndrome and diabetes mellitus duration of five years have the significant changes in sensory and motor peripheral nerves. Neuropathic changes are possible in patients with metabolic syndrome and normal glycemic control.

Download Full-text

Renoprotective opportunities of Lespedeza capitata in patients with chronic kidney disease and type 2 diabetes mellitus

KIDNEYS ◽

10.22141/2307-1257.10.3.2021.239594 ◽

2021 ◽

Vol 10 (3) ◽

pp. 162-168

Author(s):

S.V. Kushnirenko ◽

D.D. Ivanov ◽

S.A. Rotova ◽

О.V. Kushnirenko

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Antihypertensive Therapy ◽

Glucose Lowering ◽

Type 2 Dm ◽

Group I ◽

Ckd Stage ◽

Lespedeza Capitata ◽

Group Ii

Background. Today, issues of renoprotection have gone beyond the use of antihypertensive therapy alone. Stable glucose-lowering and urate-lowering therapy are integral parts of modern renoprotection, which improve the functional state of the kidneys by increasing the glomerular filtration rate (GFR) and reducing the albumin excretion rate (AER) and the albumin-to-creatinine ratio (ACR). Nevertheless, hypoazotemic therapy aimed at reducing the content of nitrogenous wastes remains the leading component of the treatment of patients with chronic kidney disease (CKD). The aim of the study is the assessment of the renoprotective potential of the drug Libera (Lespedeza capitata) in patients with CKD stages 2–3 on the background of type 2 diabetes mellitus (DM). Materials and methods. The study included 107 patients with type 2 DM, aged 19 to 75 years (female — 41.1 %, male — 58.9 %), CKD stages 2–3, micro- and macroalbuminuria (category A2 and A3). The patients were divided into two groups: group I — traditional stable glucose-lowering and antihypertensive therapy (n = 50) and group II — traditional stable glucose-lowering and antihypertensive therapy in combination with Libera (Lespedeza capitata) (n = 57), which was prescribed 1 capsule t.i.d. regardless of food intake for 3 months. The criteria for the effectiveness of treatment were dynamics of GFR, AER/ACR in daily urine. The observation period for the patients was 3 months. Results. The renoprotective potential of Lespedeza capitata (Libera) was demonstrated after 3 months of treatment in the form of a significant increase in GFR in patients with CKD stage 2 in group II up to 79.0 ± 1.4 ml/min/1.73 m2 in comparison with the initial data (p < 0.01) and the results obtained in group I after 3 months of using only traditional stable glucose-lowering and antihypertensive therapy (p < 0.05). The use of Libera in the complex treatment of patients of the II group with CKD stage 3 against the background of type 2 DM for 3 months had a positive effect on nitrogen and water excretory kidney function, which manifested itself in an improvement in GFR to 56.6 ± 2.1 ml/min/1.73 m2 in comparison with the initial data (p < 0.05) and the results obtained in group I — 50.8 ± 1.9 ml/min/1.73 m2 (p < 0.05). In group I with traditional stable glucose-lowering and antihypertensive therapy, only 3 patients (9.1 %) transferred from category A2 to category A1 (normoalbuminuria) after 3 months and 2 patients (11.8 %) from category A3 to category A2. In group II, the appointment of Lespedeza capitata (Libera) in combination with stable glucose-lowering and antihypertensive therapy facilitated the transfer of 10 patients (27.8 %) from category A2 to A1 and 7 patients (33.3 %) from category A3 to A2 (p < 0.001). Conclusions. Lespedeza capitata (Libera) in combination with traditional stable glucose-lowering and antihypertensive therapy contributes to the preservation and improvement of the filtration function of the kidneys, a decrease in AER/ACR in patients with CKD stage 2–3 (3a і 3b) against the background of type 2 DM and proves renoprotective efficiency and safety.

Download Full-text

Autoantibody as markers of the heart state in patients with vibration disease burdened diabetes mellitus

Medical Immunology (Russia) ◽

10.15789/1563-0625-aam-1739 ◽

2020 ◽

Vol 22 (2) ◽

pp. 311-318

Author(s):

L. B. Masnavieva ◽

I. V. Kudaeva ◽

Yu. A. Kuznetsova

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Thrombus Formation ◽

The State ◽

Myocardial Cells ◽

Diabetes Group ◽

Vibration Disease ◽

Group I ◽

Group Ii

Physical and chemical factors, obesity, lipid metabolism disorder, diabetes affect the state of the vascular endothelium, the processes of thrombus formation, fibrinolysis and increase the risk of developing cardiovascular diseases. It can be assumed that the development and course of pathological processes in the cardiovascular system, caused by vibration disease with the onset of diabetes, will undergo changes. The purpose of the study was to assess the state of heart condition according to the level of specific autoantibodies with the combined effect of vibration disease and type 2 diabetes mellitus. Patients with vibration disease (group I), patients with type 2 diabetes (group II) and persons with vibration disease in combination with type 2 diabetes (group III) were examined. Individuals do not have a history of coronary heart disease, stroke, and myocardial infarction have been included in obsledrovanie. Serum levels of specific autoantibodies characterizing the state of the heart have been studied. It was revealed that the content of autoantibodies to 1-adrenoreceptors in patients of group I was higher than in individuals of group II. The relative content of autoantibodies to the components of the membrane and cytoplasm of myocardial cells in patients of groups I-III did not differ. It was found that elevated levels of autoantibodies to components of the membrane and cytoplasm of myocardial cells, cardiomyosin, 1-adrenoreceptors were observed more often in patients with vibration disease combined with diabetes and in persons with vibration disease than in people with diabetes. Persons with a reduced content of autoantibodies to 1-adrenergic receptors were not detected among patients of groups I and III. Changes in the levels of specific autoantibodies in persons with vibration disease may indicate the development of functional metabolic and structural changes in the heart, disorders of its electrical activity that have not yet been manifested in the form of a pathological process. Lower levels of 1-adrenoceptor autoantibodies in patients with type 2 diabetes without vibration disease can be caused by increased levels of catecholamines, which is characteristic of diabetics. Further research, including clinical data and indicators of functional diagnostics is necessary to confirm our assumptions.

Download Full-text

The Effect of Induced Diabetes Mellitus on the Cerebellar Cortex of Adult Male Rat and the Possible Protective Role of Oxymatrine: A Histological, Immunohistochemical and Biochemical Study

10.21203/rs.3.rs-300672/v1 ◽

2021 ◽

Author(s):

Amany Mohamed Shalaby ◽

Adel Mohamed Aboregela ◽

Mohamed Ali Alabiad ◽

Mona Tayssir Sadek

Keyword(s):

Diabetes Mellitus ◽

Purkinje Cells ◽

Cerebellar Cortex ◽

Adult Male ◽

Protective Role ◽

Diabetic Rats ◽

Male Rats ◽

Group I ◽

Group Ii

Abstract Diabetes mellitus (DM) represents a widespread metabolic disease with a well-known neurotoxicity in both central and peripheral nervous systems. Oxymatrine is a traditional Chinese herbal medicine that has various pharmacological activities including; anti-oxidant, anti-apoptotic and anti-inflammatory potentials. The present work aimed to study the impact of diabetes mellitus on the cerebellar cortex of adult male albino rat and to evaluate the potential protective role of oxymatrine using different histological methods. Fifty-five adult male rats were randomly divided into three groups: group I served as control, group II was given oxymatrine (80 mg/kg/day) orally for 8 weeks and group III was given a single dose of streptozotocin (50mg/kg) intaperitoneally to induce diabetes. Then diabetic rats were subdivided into two subgroups: subgroup IIIa that received no additional treatment and subgroup IIIb that received oxymatrine similar to group II. The diabetic group revealed numerous changes in the Purkinje cell layer in the form of multilayer arrangement of Purkinje cells, shrunken cells with deeply stained nuclei as well as focal loss of the Purkinje cells. A significant increment in GFAP and synaptophysin expression was reported. Transmission electron microscopy showed irregularity and splitting of myelin sheaths in the molecular layer, dark shrunken Purkinje cells with ill-defined nuclei, dilated Golgi saccules and dense granule cells with irregular nuclear outlines in the granular layer. In contrast, these changes were less evident in diabetic rats that received oxymatrine. In conclusion, Oxymatrine could protect the cerebellar cortex against changes induced by DM.

Download Full-text

Cytokeratin 18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients

QJM ◽

10.1093/qjmed/hcaa052.010 ◽

2020 ◽

Vol 113 (Supplement_1) ◽

Author(s):

M Maher ◽

H Abdelaziz ◽

T yossif ◽

M Ossama

Keyword(s):

Fatty Liver ◽

Hepatic Steatosis ◽

Disease Severity ◽

P Value ◽

Cytokeratin 18 ◽

Alcoholic Fatty Liver ◽

Non Invasive ◽

Group I ◽

Egyptian Patients ◽

Group Ii

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which occurs when exceeive fat is deposited in the liver due to causes other than excessive alcohol use, NAFLD is subdivided into non alcoholic fatty liver (NAFLD) and nonalcoholic steatohepatitis (NASH). In NAFLD, hepatic steatosis is present without evidence of significant inflammation, whereas in NASH, hepatic steatosis is associated with hepatic inflammation Aims To evaluate the role of CK-18 as a non invasive marker in diagnosis of NASH and its usefulness in correlation with disease severity in Egyptian patients. Patients and Methods 60 subjects were divided into 2 groups: group I: including 30 patients with NAFLD, group II: including 30 matched healthy controls Diagnosis of NASH and its discrimination from NAFL was done by fibroscan. CK-18 level in plasma was measured for all subjects using ELISA. Results CK-18 was significantly elevated in patients of group I in comparison to group II, with mean ± SD: 460 ± 279, 167 ± 56 and 149 ± 57, respectively, and P value: 0.001. with mean ±SD: 59.6± 28, when compared with control group (with 23±8) P value < 0.001. ROC curve between Cases and Control regard CK18 with Area Under the Curve (AUC): 0.925. Cutoff > 30 ug/l With Sensitivity: 86.67% & Specificity: 83.33%. Ck-18 was found to correlate with steatosis and fibrosis assessed by fibroscan with P value< 0.001. Conclusion Measurement of serum cytokeratin 18 fragment levels (CK18) correlate with the Fibroscan (Transient Elastograph) as a non invasive tests in diagnosis & prognosis of non alcoholic fatty liver diseases (NAFLD).

Download Full-text

Elevated Level of Plasma B-Type Natriuretic Peptide (BNP) as a Prognostic Marker in Patients with Acute Coronary Syndrome

Bangladesh Medical Journal ◽

10.3329/bmj.v46i2.40216 ◽

2019 ◽

Vol 46 (2) ◽

pp. 32-37

Author(s):

Dilshad Parvin ◽

Md Nasir Uddin ◽

Md Shahjahn Kabir ◽

Afsana Ahmed ◽

SM Rahat Hossain ◽

...

Keyword(s):

Acute Coronary Syndrome ◽

Logistic Regression ◽

Odds Ratio ◽

Binary Logistic Regression ◽

Prognostic Indicator ◽

Morbidity And Mortality ◽

Coronary Syndrome ◽

Group I ◽

Group Ii ◽

Age Range

Acute coronary syndrome (ACS), a life-threatening manifestation of coronary artery disease, ranges from unstable angina (UA) to acute myocardial infarction (AMI). To reduce the morbidity and mortality resulting from acute coronary syndrome, we should have to find out some predictor or prognostic indicator. A prognostic indicator should be available at the time of initial patient’s evaluation, in order to maximize the potential benefits of early risk assessment. This study designed to evaluate plasma BNP as a prognostic tool in patients with acute coronary syndrome. A prognostic cohort study was carried out with 90 (ninety) acute coronary syndrome patients on the basis of their clinical and laboratory criteria with age range of 30 to 90 years in the department of biochemistry, BSMMU, in collaboration with department of cardiology, NICVD, BSMMU and BIRDEM. Plasma BNP concentrations were measured on enrollment and then grouping of the study subjects were done on the basis of their empirical cut off value of plasma BNP concentration. All the patients were free from heart failure, renal disease, thyroid disease and hepatic disorder. Main outcomes were mortality, morbidity and survival after hospital discharge with or without any disability. All the subjects were categorized into two and to see the significance between two groups in relation to age and sex Unpaired –t test and Chi square test were done. Finally, Binary logistic regression was done. Among 90 acute coronary syndromes patients, there were 74(82.2%) male and 16(17.8%) female with mean age of the study population 51.8 years and the age range of 30 t0 90 years. Among enrolled patients, 24 (26.7%) were NSTEMI and 66 (73.3%) were STEMI that includes 29 (32.2%) anterior MI, 21 (23.3%) inferior MI, 16 (17.8%) other varieties of MI. All the study subjects were grouped into two on the basis of empirical cut off value of plasma BNP 640pg/ml on enrollment. Group I with plasma BNP level less than 640pg/ml includes 57 (63.3%) subjects and group II with plasma BNP more than 640pg/ml includes 33 (36.7%) subjects. Among group I (n=57) good recovery, morbidity and mortality found to be in 41(71.9%), 15(26.3%) and 1(1.8%) patients and those in group II (n=33) found in 6(18.2%), 19(57.6%) and 8(24.2%) patients respectively. Keeping the group I in reference category binary logistic regression analysis done, showing odds ratio 11.5 with p- value 0.000. The odds ratio 11.5 indicates that there is 11.5 times higher chance of getting bad outcome in ACS patients having higher plasma BNP concentrations. Bangladesh Med J. 2017 May; 46 (2): 32-37

Download Full-text

Dietary Consumption of Virgin Coconut Oil Ameliorates Lipid Profiles in Diabetic Rats

Physiology Journal ◽

10.1155/2014/256236 ◽

2014 ◽

Vol 2014 ◽

pp. 1-5 ◽

Cited By ~ 2

Author(s):

A. M. Akinnuga ◽

S. O. Jeje ◽

O. Bamidele ◽

V. E. Sunday

Keyword(s):

Diabetes Mellitus ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Coconut Oil ◽

Very Low Density Lipoprotein ◽

Low Density ◽

Virgin Coconut Oil ◽

Group Iii ◽

Group I ◽

Group Ii

Virgin coconut oil (VCO) is a saturated fat with promising antidiabetic properties but its ameliorative effect on lipid profiles in diabetics is rarely reported. Therefore, in this study, a total of fifteen (15) male rats weighing 200–250 g were divided into 3 experimental groups (n=5). Group I (control) and Group II (diabetic control group) were fed a normal rat chow while Group III (diabetic test group) was fed a 10% VCO diet for 3 weeks. Group II and Group III were made diabetic by intraperitoneal injection of 150 mg/kg of alloxan. After 72 hours of injection, blood glucose was tested to confirm diabetes mellitus. After 3 weeks, the animals were sacrificed to collect blood samples for lipid profile analysis. The results showed a significant increase in concentrations of triglyceride, total cholesterol, low density lipoprotein, and very low density lipoprotein and decrease in concentration of high density lipoprotein in Group II when compared to Group I. Also, the concentrations of triglyceride, total cholesterol, low density lipoprotein, and very low density lipoprotein except high density lipoprotein significantly reduced in Group III when compared to Group II (P<0.01, 0.001). VCO consumption can be claimed to ameliorate lipid levels in diabetes mellitus.

Download Full-text